PROTOCOLOS CLÍNICOS E DIRETRIZES TERAPÊUTICAS

Miastenia Gravis Miastenia Gravis 30. Bromberg MB, Wald JJ, Forshew DA, Feldman EL, Albers JW. Randomized trial of azathioprine or prednisone for initial immunosuppressive treatment of myasthenia gravis. J Neurol Sci. 1997;150(1):59-62. 31. A randomized clinical trial comparing prednisone and azathioprine in myasthenia gravis. Results of the second interim analysis. Myasthenia Gravis Clinical Study Group. J Neurol Neurosurg Psychiatry. 1993;56(11):1157-63. 32. Tindall RS, Rollins JA, Phillips T, Greenlee RG, Wells L, Belendiuk G. Preliminary results of a double-blind, randomized, placebo-controlled trial of cyclosporine in myasthenia gravis. N Engl J Med. 1987;316(12):719-24. 33. Tindall RS, Phillips T, Rollins JA, Wells L, Hall K. A clinical therapeutic trial of cyclosporine in myasthenia gravis. Ann N Y Acad Sci. 1993;681:539-51. 34. Ciafaloni E, Nikhar NK, Massey JM, Sanders DB. Retrospective analysis of the use of cyclosporine in myasthenia gravis. Neurology. 2000;55(3):448-50. 35. Hart IK, Sathasivam S, Sharshar T. Immunosuppressive agents for myasthenia gravis. Cochrane Database Syst Rev. 2007;(4):CD005224. 36. De Feo LG, Schottlender J, Martelli NA, Molfino NA. Use of intravenous pulsed cyclophosphamide in severe, generalized myasthenia gravis. Muscle Nerve. 2002;26(1):31-6. 37. Fateh-MoghadamA, Wick M, Besinger U, Geursen RG. High-dose intravenous gammaglobulin for myasthenia gravis. Lancet. 1984;1(8381):848-9. 38. Gajdos P, Outin HD, Elkharrat D, Brunel D, de Rohan-Chabot P, Raphael JC, et al. High-dose intravenous gammaglobulin for myasthenia gravis. Lancet. 1984;1(8373):406-7. 39. Arsura EL. Experience with intravenous immunoglobulin in myasthenia gravis. Clin Immunol Immunopathol. 1989;53(2 Pt 2):S170-9. 40. Gajdos P, Outin HD, Morel E, Raphael JC, Goulon M. High dose intravenous gamma globulin for myasthenia gravis: an alternative to plasma exchange. Ann N Y Acad Sci. 1987;505:842-44. 41. Cosi V, Lombardi M, Piccolo G, Erbetta A. Treatment of myasthenia gravis with high dose intravenous immunoglobulin. Acta Neurol Scand. 1991;84(2):81-4. 42. Zinman L, Ng E, Bril V. IV immunoglobulin in patients with myasthenia gravis: a randomized controlled trial. Neurology. 2007;68(11):837-41. 43. Achiron A, Barak Y, Miron S, Sarova-Pinhas I. Immunoglobulin treatment in refractory myasthenia gravis. Muscle Nerve. 2000;23(4):551-5. 44. Hilkevich O, Drory VE, Chapman J, Korczyn AD. The use of intravenous immunoglobulin as maintenance therapy for myasthenia gravis. Clin Neuropharmacol. 2001;24(3):173-6. 45. Gajdos P, Chevret S, Clair B, Tranchant C, Chastang C. Clinical trial of plasma exchange and high-dose intravenous immunoglobulin in myasthenia gravis. Myasthenia Gravis Clinical Study Group. Ann Neurol. 1997;41(6):789-96. 46. Wolfe GI, Barohn RJ, Foster BM, Jackson CE, Kissel JT, Day JW, et al. Randomized, controlled trial of intravenous immunoglobulin in myasthenia gravis. Muscle Nerve. 2002;26(4):549-52. 47. Gajdos P, Tranchant C, Clair B, Bolgert F, Eymard B, Stojkovic T, et al. Treatment of myasthenia gravis exacerbation with intravenous immunoglobulin: a randomized double-blind clinical trial. Arch Neurol. 2005;62(11):1689-93. 48. Dalakas MC. Intravenous immunoglobulin in the treatment of autoimmune neuromuscular diseases: present status and practical therapeutic guidelines. Muscle Nerve. 1999;22(11):1479-97. 49. Evoli A, Di Schino, Marsili F, Punzi C. Successful treatment of myasthenia gravis with tacrolimus. Muscle Nerve. 2002;25(1):111-4. 50. Yoshikawa H, Mabuchi K, Yasukawa Y, Takamori M, Yamada M. Low-dose tacrolimus for intractable myasthenia gravis. J Clin Neursosci. 2002;9(6):627-8. 51. Meriggioli M, Rowin J. Treatment of myasthenia gravis with mycophenolate: a case report. Muscle Nerve. 2000;23(8):1287-9. 52. Schneider C, Gold R, Reiners K, Toyka KV. Mycophenolate mofetil in the therapy of severe myasthenia gravis. Eus Neurol. 2001;46(2):79-82. 53. Ciafaloni E, Massey JM, Tucker-Lipscomb B, Sanders DB. Mycophenolate mofetil for myasthenia gravis: an open label study. Neurology. 2001;56(1):97-9. 54. Nagane Y, Utsugisawa K, Obara D, Kondoh R, Terayama Y. Efficacy of low-dose FK506 in the treatment of Myasthenia gravis – a randomized pilot study. Eur Neurol. 2005;53(3):146-50. Epub 2005 May 17. 475